Pharvaris (PHVS) Competitors $23.39 +0.21 (+0.91%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$23.44 +0.04 (+0.19%) As of 10/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. KRYS, PTCT, MENS, ARWR, ACLX, PCVX, CRNX, PTGX, KYMR, and MLTXShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Jyong Biotech (MENS), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Vaxcyte (PCVX), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Its Competitors Krystal Biotech PTC Therapeutics Jyong Biotech Arrowhead Pharmaceuticals Arcellx Vaxcyte Crinetics Pharmaceuticals Protagonist Therapeutics Kymera Therapeutics MoonLake Immunotherapeutics Pharvaris (NASDAQ:PHVS) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation. Which has more volatility and risk, PHVS or KRYS? Pharvaris has a beta of -2.77, indicating that its share price is 377% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Which has stronger earnings & valuation, PHVS or KRYS? Krystal Biotech has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$145.24M-$3.36-6.96Krystal Biotech$290.52M18.27$89.16M$4.9237.27 Does the media prefer PHVS or KRYS? In the previous week, Krystal Biotech had 2 more articles in the media than Pharvaris. MarketBeat recorded 4 mentions for Krystal Biotech and 2 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.25 beat Krystal Biotech's score of 1.21 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend PHVS or KRYS? Pharvaris currently has a consensus target price of $34.00, indicating a potential upside of 45.36%. Krystal Biotech has a consensus target price of $209.00, indicating a potential upside of 13.98%. Given Pharvaris' higher possible upside, equities analysts plainly believe Pharvaris is more favorable than Krystal Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is PHVS or KRYS more profitable? Krystal Biotech has a net margin of 40.85% compared to Pharvaris' net margin of 0.00%. Krystal Biotech's return on equity of 15.21% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -69.09% -63.34% Krystal Biotech 40.85%15.21%13.81% Do institutionals and insiders believe in PHVS or KRYS? 86.3% of Krystal Biotech shares are owned by institutional investors. 11.8% of Pharvaris shares are owned by company insiders. Comparatively, 13.7% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryKrystal Biotech beats Pharvaris on 13 of the 15 factors compared between the two stocks. Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.65%4.69%P/E Ratio-6.9622.2886.9626.71Price / SalesN/A458.33604.82131.77Price / CashN/A47.8637.9061.31Price / Book4.229.9312.556.55Net Income-$145.24M-$52.80M$3.31B$277.50M7 Day Performance-3.23%5.22%4.28%2.42%1 Month Performance1.48%10.61%6.90%8.63%1 Year Performance28.52%25.03%70.54%31.60% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris2.2907 of 5 stars$23.39+0.9%$34.00+45.4%+28.5%$1.22BN/A-6.9630Positive NewsGap DownKRYSKrystal Biotech4.6773 of 5 stars$176.75+5.3%$209.00+18.2%+3.5%$4.86B$290.52M35.92210Positive NewsPTCTPTC Therapeutics3.4237 of 5 stars$60.65+2.8%$69.00+13.8%+86.2%$4.69B$806.78M8.701,410MENSJyong BiotechN/A$50.00-16.3%N/AN/A$4.54BN/A0.0031ARWRArrowhead Pharmaceuticals4.1691 of 5 stars$33.78+3.0%$43.14+27.7%+91.9%$4.53B$572.98M-26.39400Insider TradeACLXArcellx2.2263 of 5 stars$79.11-0.8%$114.31+44.5%+8.7%$4.42B$56.98M-23.1380Insider TradePCVXVaxcyte2.4646 of 5 stars$34.65+2.0%$106.25+206.6%-61.7%$4.41BN/A-8.43160Positive NewsCRNXCrinetics Pharmaceuticals3.9309 of 5 stars$43.51-5.2%$73.20+68.2%-23.1%$4.32B$1.04M-10.59210Analyst ForecastInsider TradePTGXProtagonist Therapeutics2.1551 of 5 stars$65.14-3.4%$68.36+4.9%+46.1%$4.19B$434.43M93.06120Positive NewsKYMRKymera Therapeutics1.9279 of 5 stars$58.50+4.0%$59.95+2.5%+34.5%$4.02B$47.07M-16.86170Analyst ForecastMLTXMoonLake Immunotherapeutics2.9744 of 5 stars$6.24-89.9%$57.00+813.5%-84.8%$3.98BN/A-2.242Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Krystal Biotech Alternatives PTC Therapeutics Alternatives Jyong Biotech Alternatives Arrowhead Pharmaceuticals Alternatives Arcellx Alternatives Vaxcyte Alternatives Crinetics Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Kymera Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHVS Stock Alerts